title: Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
authors.affiliation: Athens University, Greece. psfikakis@med.uoa.gr
authors.forename: P P
authors.initials: PP
authors.lastname: Sfikakis
authors.forename: N
authors.initials: N
authors.lastname: Markomichelakis
authors.forename: E
authors.initials: E
authors.lastname: Alpsoy
authors.forename: S
authors.initials: S
authors.lastname: Assaad-Khalil
authors.forename: B
authors.initials: B
authors.lastname: Bodaghi
authors.forename: A
authors.initials: A
authors.lastname: Gul
authors.forename: S
authors.initials: S
authors.lastname: Ohno
authors.forename: N
authors.initials: N
authors.lastname: Pipitone
authors.forename: M
authors.initials: M
authors.lastname: Schirmer
authors.forename: M
authors.initials: M
authors.lastname: Stanford
authors.forename: B
authors.initials: B
authors.lastname: Wechsler
authors.forename: C
authors.initials: C
authors.lastname: Zouboulis
authors.forename: P
authors.initials: P
authors.lastname: Kaklamanis
authors.forename: H
authors.initials: H
authors.lastname: Yazici
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy*; D016903:Drug Monitoring / Q000379:methods; D000068800:Etanercept; D019317:Evidence-Based Medicine; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D018579:Patient Selection; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept